Overview
Global thrombectomy devices market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
A thrombectomy is a surgery to remove a blood clot from a blood vessel (artery or vein). A blood clot, also known as a thrombus, can interrupt the blood flow to extremities and/or organs that can be limb or life-threatening. Some of the most common places for blood clots to occur are your legs, arms, intestines, brain, lungs and heart.
Thrombectomy devices are medical instruments specifically designed to remove blood clots, medically known as thrombi, from blood vessels. These devices are utilized primarily in the treatment of conditions where blood clots obstruct or impede blood flow within arteries or veins. Thrombectomy procedures involve the mechanical extraction, fragmentation or dissolution of blood clots to restore normal blood flow and prevent further complications such as tissue damage or organ dysfunction.
Market Dynamics: Drivers
Rising adoption for various cardiovascular conditions
The rising adoption of thrombectomy devices for various cardiovascular conditions is expected to drive the market over the forecast period. Clinical studies have demonstrated the effectiveness of thrombectomy devices in improving patient outcomes for conditions such as acute ischemic stroke, peripheral artery disease, deep vein thrombosis (DVT) and pulmonary embolism. As a result, healthcare providers are increasingly turning to thrombectomy as a primary or adjunctive treatment option.
For instance, on June 08, 2023, Inari Medical launched two new purpose-built thrombectomy catheters to address the needs of venous stent thrombosis and venous thromboembolism. The two products are the Triever16 Curve catheter and the RevCore thrombectomy catheter. Part of the FlowTriever platform, the Triever16 Curve catheter is designed for use in both peripheral thrombectomy and pulmonary embolism procedures.
Thrombectomy procedures are minimally invasive compared to traditional surgical interventions, offering advantages such as shorter recovery times, reduced hospital stays and lower risk of complications. Patients and healthcare providers alike are attracted to the less invasive nature of thrombectomy, leading to greater adoption. Continuous innovations in thrombectomy device technology have improved procedural success rates and patient outcomes. Advances in device design, materials and techniques have enhanced device performance, safety and ease of use.
For instance, on October 14, 2021, phenox expanded its technology portfolio for acute ischemic stroke with the global launch of the pRESET 6-50 mechanical thrombectomy device. Adding to their already extensive technology portfolio, phenox introduced the pRESET 6-50 mechanical thrombectomy device for the treatment of acute large vessel occlusive (LVO) stroke. This latest addition makes the pRESET 6-50 the longest stent retriever in the phenox portfolio and one of the longest stent retrievers available on the market for mechanical thrombectomy.
Further, the increasing prevalence of various neurovascular conditions, rising FDA approvals for novel products, increasing awareness about thrombectomy devices and advancements in the development of various types of devices with advanced features are the factors expected to drive the market over the forecast period.
Restraints
Factors such as the high cost associated with the thrombectomy procedures, availability of alternative treatments and limited awareness about the devices are the factors expected to hamper the market.
For more details on this report - Request for Sample

Segment Analysis
The global thrombectomy devices market is segmented based on product type, application, end-user and region.
The mechanical thrombectomy devices segment accounted for approximately 56.3% of the thrombectomy devices market share
The mechanical thrombectomy devices segment is expected to hold the largest market share over the forecast period. Mechanical thrombectomy devices are indeed highly used in clinical practice for the treatment of various vascular occlusive diseases, particularly acute ischemic stroke. Mechanical thrombectomy involves physically engaging with the blood clot to capture, entrap or mechanically disrupt it, allowing for its extraction from the affected blood vessel. These devices have become a cornerstone of treatment in many cases due to their effectiveness, safety and ability to achieve rapid revascularization.
For instance, on January 11, 2023, Penumbra, a Calif.-based global healthcare company cleared the U.S. Food & Drug Administration (FDA) clearance and launched Lightning Flash, which the company reports is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus. Next-generation technology combines superior catheter design with the latest dual clot detection innovation.
In addition, in June 2020, phenox launched the pRESET 5–40 and pRESET LUX 4–20 thrombectomy devices after receiving CE mark approval last year. The pRESET device is a stentriever that is used for mechanical thrombectomy in patients with acute ischaemic stroke, due to large vessel occlusion. Over the past few years, safety and efficacy using mechanical thrombectomy have been proven in patients with large vessel occlusion in four major randomized controlled trials. The pRESET thrombectomy device was evaluated in the ARTESp study and demonstrated its safety and efficacy.
Continuous innovations in mechanical thrombectomy device technology have led to the development of highly efficient and navigable devices. Modern thrombectomy devices, such as stent retrievers and aspiration catheters, offer improved trackability, flexibility and thrombus engagement capabilities, making them easier to use and more effective in clot retrieval.
For instance, on September 24, 2020, Royal Philips launched the innovative QuickClear mechanical thrombectomy system. The compact, single-use system provides an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems. The system’s innovative all-in-one design is simple to use while eliminating the need for capital equipment or costly accessories, with easy setup supporting faster procedure times. The Philips QuickClear Mechanical Thrombectomy System has received U.S. FDA clearance and is available for sale in the U.S.

Geographical Analysis
North America accounted for approximately 43.5% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and rising technological advancements in thrombectomy devices. North America especially the United States is a home for its strong presence of major players such as various medical device companies.
The region is also a hub for medical device innovation and research. Many leading thrombectomy device manufacturers are based in the region, driving continuous advancements in device design, functionality and performance. This innovation fosters greater adoption of thrombectomy devices among healthcare providers and patients.
For instance, on June 14, 2023, Surmodics, Inc. received U.S. Food and Drug Administration (FDA) clearance for its Pounce LP (Low Profile) Thrombectomy System. The Pounce system is the first mechanical thrombectomy device designed to promptly remove organized thrombus or embolus without the need for capital equipment, thrombolytics or aspiration.
Described as a “grab-and-go” solution, the Pounce system is both readily deployable and simple to use. The system is composed of three components: a 5 Fr delivery catheter, a basket wire, and a funnel catheter. The basket wire is delivered distal to the location of the thrombus, deploying two nitinol self-expanding baskets. The baskets capture the clot and are retracted into the nitinol collection funnel. With the clot entrained, the system is withdrawn into a minimum 7 Fr guide sheath through which the clot is removed from the body.
Competitive Landscape
The major global players in the thrombectomy devices market include Medtronic plc, Boston Scientific Corporation, Penumbra, Inc., Acandis GmbH, Stryker Corporation, Terumo Corporation, Argon Medical Devices, Teleflex Incorporated, Merit Medical Systems and phenox GmbH among others.

COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global thrombectomy devices market. During the coronavirus disease 2019 (COVID-19) pandemic, many hospitals and healthcare facilities were overwhelmed with COVID-19 patients, leading to the cancellation or postponement of thrombectomy interventions. Patients with acute ischemic stroke or other vascular occlusive diseases may have experienced delays in accessing thrombectomy treatment, which could have impacted their outcomes.
Market Segmentation
By Product Type


    • Hydrodynamic Thrombectomy Devices
    • Aspiration Thrombectomy Devices
    • Mechanical Thrombectomy Devices
    • Percutaneous Thrombectomy Devices


By Application


  • • Ischemic Stroke
    • Peripheral Artery Disease
    • Pulmonary Embolism
    • Deep Vein Thrombosis
    • Coronary Artery Disease (CAD)
    • Others


By End-User


  • • Hospitals
    • Specialty Clinics
    • Academic and Research Institutes
    • Others


By Region


  • • North America


o U.S.
o Canada
o Mexico


  • • Europe


o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe


  • • South America


o Brazil
o Argentina
o Rest of South America


  • • Asia-Pacific


o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific


  • • Middle East and Africa


Why Purchase the Report?


  • • To visualize the global thrombectomy devices market segmentation based on product type, application, end-user and region as well as understand key commercial assets and players.
    • Identify commercial opportunities by analyzing trends and co-development
    • Excel data sheet with numerous data points of thrombectomy devices market-level with all segments.
    • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
    • Product mapping available as excel consisting of key products of all the major players.


The global thrombectomy devices market report would provide approximately 61 tables, 63 figures and 187 Pages.
Target Audience 2024


  • • Manufacturers/ Buyers
    • Industry Investors/Investment Bankers
    • Research Professionals
    • Emerging Companies